Importantly, in an exploratory cohort of 60 CLL patients receiving frontline immunochemotherapy, increased levels of soluble LFA-3 were found to correlate with shorter overall survival. This evidence concerns the gene CD58 and B-cell chronic lymphocytic leukemia.